On page 836, the following sentence implies that an assay reported in 1999 by McDonald and colleagues was used to discover Raf kinase inhibitors that led to sorafenib: "When the project team was formed in 1994, the reagents and assays were available to identify a Raf kinase inhibitor. A scintillation proximity assay for the high-throughput screening (HTS) and identification of selective Raf/MEK/ERK enzyme inhibitors had already been developed by McDonald et al. at Glaxo-Wellcome Inc., showing that this approach was feasible 32 ."
